Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Prevention (PREV)

CTN 308: Estrogen and Probiotic Treatment for Vaginal Health

Improving vaginal health to decrease biological risk of HIV-1 infection in Canadian ACB women

Print Friendly, PDF & Email

About the study (objectives)

This pilot trial will compare the effects of low-dose estrogen, a probiotic, or both, to improve the health of the vaginal microbiota and decrease the risk of HIV infection in pre-menopausal women.

About the disease/condition (background/context)

The risk of HIV acquisition in women is roughly double that of men, due in part to a risk of inflammation in the female genital tract. Susceptibility to sexual transmission of infections, such as HIV, can be affected by different levels and types of various naturally occurring bacteria (vaginal flora), known as the vaginal microbiota. The hormone estrogen is thought to encourage the development of type of bacteria (Lactobacilli) and decrease inflammation. Vaginal flora that may increase HIV susceptibility appears to be more common in Black and Hispanic women, compared to White and Asian women.

CTN 308 will test a whether a protective vaginal microbiota can be developed in African, Caribbean, and Black (ACB) women who have flora that may put them at a greater susceptibility to HIV infection.

Study Approach (methodology)

This study aims to recruit 80 ACB women; participants will be randomized to receive a 30-day course of one of the following treatments:

  • A low-dose estrogen vaginal ring
  • A low-dose estrogen vaginal ring with a vaginal probiotic
  • A low-dose estrogen vaginal ring with an oral probiotic
  • A vaginal probiotic alone

Participants will undergo blood, vaginal, and cervical testing at baseline, during the study, and after completion of treatment. Participants will also be asked to take vaginal swabs at home, to be tested for microbial levels at a later date.

As a pilot study, CTN 308 will primarily focus on the safety and tolerability of these treatments in combination, however, changes in vaginal health, inflammation, and HIV susceptibility will also be investigated.

Eligibility criteria


  • Women 18-49 years of age
  • Uterus and cervix present
  • Recruited through the Women’s Health in Women’s Hands (WHIWH) community Health Clinic
  • Able to understand, comply, and consent to protocol requirements and instructions
  • Able to attend scheduled study visits and complete required investigations
  • Negative pregnancy test
  • Currently practicing barrier or non-hormonal forms of contraception, and planning to continue, for the duration of the study (barrier contraceptive, abstinence)
  • Willing to undergo a pelvic exam by a female nurse
  • Willing to abstain from sexual activities for 48 hours prior to sampling

Not Allowed:

Additional Information

If you would like more information on this clinical study, please refer to the principal investigator.

Participating Site


Qualified Investigator
Dr. Jesleen Rana
Women’s Health in Women’s
Hands Community Health Centre
2 Carlton St Suite 500,
Toronto, ON M5B 1J3

Research Nurse:
Ms. Junic Wokuri
Women’s Health in Women’s
Hands Community Health Centre
2 Carlton St Suite 500,
Toronto, ON M5B 1J3
Office: 416-593-7655 Ext: 4897
Cell: 647-614-7655

Principal Investigators

Dr. Charu Kaushic
McMaster University
Hamilton, ON L8S 4L8

Dr. Fiona Smaill
McMaster University
Medical Centre
Hamilton, ON L8N 3Z5

Latest News

The enigma of HIV’s effects on aging

| Uncategorized | No Comments

The average age of people living with HIV in Canada is rising. CTN and BC-CfE researchers are working to understand the factors associated with aging in HIV. This story was originally published by BC-CfE.

Guest Blog: Dr. Haneesha Mohan

| Uncategorized | No Comments

Dr. Haneesha Mohan, CTN Postdoctoral Research Fellow at the University Health Network, describes her work on understanding the metabolic diseases and birth defects potentially caused by ARV medications.

Let’s Talk About Stigma: HIV in 2020

| Uncategorized | No Comments

We talked to three community members to get their unique perspectives on the pervasive impact of HIV-related stigma and what we can do to combat it

Could Cannabis Help Prevent HIV-Related Illnesses?

| Uncategorized | No Comments

CTN Investigators Drs. Cecilia Costiniuk and Ali Jenabian publish a thorough editorial review of cannabis research in HIV and inflammation

Research for treatments, prevention and a cure